Ending tobacco-caused mortality and morbidity: The case for performance standards for tobacco products

Tobacco Control

Volumn 22, Issue SUPPL. 1, 2013, Pages

  Hatsukami, Dorothy K ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NICOTINE; NICOTINE GUM;

ARTICLE; HUMAN; MORTALITY; QUALITY CONTROL; SMOKING; STANDARD; TOBACCO; TOBACCO INDUSTRY;

HUMANS; NICOTINE; QUALITY CONTROL; SMOKING; TOBACCO INDUSTRY; TOBACCO PRODUCTS; TOBACCO USE CESSATION PRODUCTS;

EID: 84887219791     PISSN: 09644563     EISSN: 14683318     Source Type: Journal    
DOI: 10.1136/tobaccocontrol-2012-050785     Document Type: Note

References (24)

1. Zeller M, Hatsukami D. The strategic dialogue on tobacco harm reduction: a vision and blueprint for action in the US. Tob Control 2009;18:324-32.
2. Benowitz NL, Hall SM, Stewart S, et al. Nicotine and carcinogen exposure with smoking of progressively reduced nicotine content cigarette. Cancer Epidemiol Biomarkers Prev 2007;16:2479-85.
3. Benowitz NL, Dains KM, Hall SM, et al. Smoking behavior and exposure to tobacco toxicants during 6 months of smoking progressively reduced nicotine content cigarettes. Cancer Epidemiol Biomarkers Prev 2012;21:761-9.
4. Hatsukami D, Kotlyar M, Hertsgaard LA, et al. Reduced nicotine content cigarettes: effects on toxicant exposure, dependence and cessation. Addiction 2010;105:343-55.
5. Walker N, Howe C, Bullen C, et al. The combined effect of very low nicotine content cigarettes, used as an adjunct to usual Quitline care (nicotine replacement therapy and behavioural support), on smoking cessation: a randomized controlled trial. Addiction 2012;107:1857-67.
6. Hatsukami D, Perkins KA, Lesage MG, et al. Nicotine reduction revisited: science and future directions. Tob Control 2010;19:e1-10.
7. Hatsukami DK, Benowitz NL, Donny E, et al. Nicotine reduction: strategic research plan. Nicotine Tob Res Published Online First: 25. Oct 2012. doi:10.1093/ntr/nts214
8. Henningfield JE, Benowitz NL, Slade J, et al. Reducing the addictiveness of cigarettes. Council on Scientific Affairs, American Medical Association. Tob Control 1998;7:281-93.
9. Connolly GN. The marketing of nicotine addiction by one oral snuff manufacturer. Tob Control 1995;4:73-9.
10. Oliver AJ, Jensen JA, Rogel RI, et al. Flavored and nonflavored smokeless tobacco products: rate, pattern of use, and effects. Nicotine Tob Res 2012;15:88-92.
11. Stanfill SB, Connolly GN, Zhang L, et al. Global surveillance of oral tobacco products: total nicotine, unionised nicotine and tobacco-specific N-nitrosamines. Tob Control 2011;20:e2.
12. Stepanov I, Jensen J, Hatsukami D, et al. New and traditional smokeless tobacco: comparison of toxicant and carcinogen levels. Nicotine Tob Res 2008;10: 1773-82.
13. Richter P, Hodge K, Stanfill S, et al. Surveillance of moist snuff total nicotine, pH, moisture, un-ionized nicotine, and tobacco-specific nitrosamine content. Nicotine Tob Res 2008;10:1645-52.
14. International Agency for Research on Cancer. Smokeless tobacco and some tobacco-specific nitrosamines. IARC monographs on the evaluation of carcinogenic risks to humans. Lyon, France: IARC, 2007:89.
15. Boffetta P, Straif K. Use of smokeless tobacco and risk of myocardial infarction and stroke: systematic review with meta-analysis. BMJ 2009;339:b3060.
16. Royal College of Physicians. Harm reduction in nicotine addiction: helping people who can't quit. A report by the Tobacco Advisory Group of the Royal College of Physicians. London: Royal College of Physicians, 2007.
17. Boffetta P, Hecht S, Gray N, et al. Smokeless tobacco and cancer. Lancet Oncol 2008;9:667-75.
18. McNeill A, Foulds J, Bates C. Regulation of nicotine replacement therapies (NRT): a critique of current practice. Addiction 2001;96:1757-68.
19. Sumner W II. Estimating the health consequences of replacing cigarettes with nicotine inhalers. Tob Control 2003;12:124-32.
20. Picciotto MR, Brunzell DH, Caldarone BJ. Effect of nicotine and nicotinic receptors on anxiety and depression. Neuroreport 2002;13:1097-106.
21. Picciotto MR, Caldarone BJ, King SL, et al. Nicotinic receptors in the brain. Links between molecular biology and behavior. Neuropsychopharmacology 2000;22:451-65.
22. Levin ED, McClernon FJ, Rezvani AH. Nicotinic effects on cognitive function: behavioral characterization, pharmacological specification, and anatomic localization. Psychopharmacology 2006;184:523-39.
23. Cordero-Erausquin M, Marubio LM, Klink R, et al. Nicotinic receptor function: new perspectives from knockout mice. Trends Pharmacol Sci 2000;21:211-7.
24. Mudo G, Belluardo N, Fuxe K. Nicotinic receptor agonists as neuroprotective/ neurotrophic drugs. Progress in molecular mechanisms. J Neural Transm 2007;114:135-47.